Microbix Assisting EMQN with Novel Genetic-Test EQA Program
For Rapid Identification of Patients Susceptible to Antibiotic-Induced Hearing Loss MISSISSAUGA, CANADA & MANCHESTER, UK – December 10, 2024 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and EMQN CIC (EMQN), a global supplier of laboratory external quality assessment (“EQA”) schemes for human genomic testing, announce the go-live […]
EMQN launches new EQA scheme for MT-RNR1 POCT for use with the Genedrive® MT-RNR1 ID Kit
EMQN CIC is pleased to announce the launch of a new EQA scheme for MT-RNR1 Point-of-Care Testing (POCT), suitable for use with the NICE-approved Genedrive® MT-RNR1 ID Kit. This scheme is designed to support the accurate identification of patients in acute clinical settings who carry the MT-RNR1 m.1555A>G variant, ensuring they receive alternative antibiotics to prevent hearing loss. This […]
EMQN-ERN GENTURIS: HBOC genetic testing guidelines
EMQN is honoured that ERN GENTURIS has decided to endorse our best practice guidelines: “EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer (HBOC).” ERN GENTURIS is the European Reference Network (ERN) for all patients with rare genetic tumour risk syndromes. A team of assessors, consisting of HBOC experts and an […]
EMQN CIC & Informed Genomics: validating lab results
24 September 2024, Birmingham & Manchester, UK – Informed Genomics, the UK-based genomic testing laboratory delivering innovative ISO accredited services, has been selected by EMQN CIC to provide tumour profiling services to support their quality assurance services. Informed Genomics offers comprehensive next-generation sequencing (NGS) cancer mutation analyses from solid tumour and cell-free DNA in a […]
The new 2025 catalogue is now available!
We are proud to present to you the new EQA schemes for 2025, allowing more flexibility, time and cost efficiency, ease of purchase, and more. Our goal is to ensure the highest genomic diagnostic quality from lab to patient, and our updated schemes will help you get there, tailoring our services to your needs. Some of […]
In 2025, flexibility is our goal
You spoke and we listened! In 2025, we will be piloting changes to our scheme portfolio to enable more flexibility when participating in EQA. New for 2025, the hereditary hearing loss scheme has options to participate in EQA for either targeted DFNB1 locus testing, or for gene panel testing, enabling you to choose the […]